Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study

Mater Today Bio. 2023 Dec 7:24:100905. doi: 10.1016/j.mtbio.2023.100905. eCollection 2024 Feb.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), characterized by its high fatality rate and contagious nature, has led to significant morbidity and mortality worldwide, significantly impacting both our daily lives and public health. The respiratory pathway serves as the primary route for SARS-CoV2 propagation within the human body, with the lung acting as the initial target organ. Simultaneously, the lung functions as a protective barrier, preventing the entry of viruses into the bloodstream through the alveolar-capillary barrier. Bioengineered microfluidic lung chips, utilizing advanced near-to-native technologies, offer a novel perspective for comprehending the intricate workings of human lungs and facilitating the discovery of anti-coronavirus drugs to combat the challenges posed by coronavirus disease 2019 (COVID-19). This review aims to introduce the key elements and design types of artificial lung chips that closely resemble in vivo-like niches in terms of both structure and function. Furthermore, quantitative and qualitative techniques for evaluating the functionality of the alveolar-capillary barrier are summarized, confirming the successful construction of lung chip systems through engineering approaches. The prospects and persistent challenges associated with establishing next-generation artificial lung models to meet the demands of virology studies are also discussed.

Keywords: Bioengineering technology; COVID-19 research; Human-relevant model system; Lung chip design; Systemic disease.

Publication types

  • Review